RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer
RSC4All accurately reproduces RSClin™ predictions and reclassification patterns, providing a freely accessible alternative where RSClin™ is unavailable. By integrating CP and genomic data, it refines risk stratifications and supports adjuvant decisions in N0 HR-positive/HER2-negative eBC. External validation in an independent cohort strengthens its generalizability and clinical applicability.
Authors
- Monica Fornier (ORCID: https://orcid.org/0000-0003-3326-5972)
- C. Benvenuti (ORCID: https://orcid.org/0009-0001-9805-8117)
- Salvatore D’Amico (ORCID: https://orcid.org/0000-0003-1801-7575)
- Rita De Sanctis (ORCID: https://orcid.org/0000-0003-3202-1933)
- Alberto Zambelli (ORCID: https://orcid.org/0000-0002-1374-1831)
- R. Buonaiuto
- Federica Martorana (ORCID: https://orcid.org/0000-0001-5062-2914)
- Grazia Arpino (ORCID: https://orcid.org/0000-0002-4074-2530)
- Marika Del Gaudio
- Paolo Vigneri (ORCID: https://orcid.org/0000-0002-5943-6066)
- Carlo Tondini (ORCID: https://orcid.org/0000-0003-0635-8954)
- Emanuela Ferraro (ORCID: https://orcid.org/0000-0001-5863-2391)
- Mario Giuliano (ORCID: https://orcid.org/0000-0003-0835-3153)
- Rossana Di Rienzo
- Flavia Jacobs (ORCID: https://orcid.org/0000-0001-9126-8325)
- Giuseppe Saltalamacchia (ORCID: https://orcid.org/0000-0002-0247-3835)
- Evandro de Azambuja (ORCID: https://orcid.org/0000-0001-9501-4509)
- Elisa Agostinetto (ORCID: https://orcid.org/0000-0003-0295-7511)
- Riccardo Gerosa
- Matteo Giovanni Della Porta (ORCID: https://orcid.org/0000-0002-6915-5970)
- Elena Zazzetti (ORCID: https://orcid.org/0009-0002-7234-9482)
- Armando Santoro (ORCID: https://orcid.org/0000-0003-1709-9492)
- Alessandra Chirco (ORCID: https://orcid.org/0000-0001-5481-4972)
Institutions
- Université Libre de Bruxelles (BE)
- Memorial Sloan Kettering Cancer Center (US)
- Humanitas University (IT)
- Institut Jules Bordet (BE)
- University of Catania (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Scuola Superiore Meridionale (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105830
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- Les Laboratories Pierre Fabre
- Myriad Genetics
- Incyte
- Seagen
- Eisai
- European Society for Medical Oncology
- Servier
- Ipsen
- Daiichi Sankyo Europe